Covid-19: Five held in Bengaluru for black marketing of Remdesivir

In two separate incidents, Bengaluru police have arrested five persons for selling Remdesivir injections at eight to 10 times more than the prescribed rates of the antiviral drug, the police said on Saturday.

Bengaluru North division police arrested these five persons in two separate incidents. In the first case, four persons were arrested from the Mahalakshmi Layout police limits, while another person was arrested from the Sriramapura police limits.

The police identified the accused persons as Shivakumar, 32, a bank manager in the cooperative sector; Darshan, 29, a medical representative; Girish, 30, a lab technician, and Nagesh, 43, a vegetable vendor.

The fifth arrested person has been identified as Nayaz Ahmed, 30, an employee with an online pharma delivery company.

The police said that all these accused persons were selling the drug for as high as Rs 35,000 to Rs 40,000 per vial.

The accused bank manger used the gullible vegetable vendor to sell these vials by making the purchasers believe that he was in possession of them as one of his relatives died of Covid recently and the family was in possession of these medicines and all he wanted was to sell them at a price at which he had reportedly purchased them.

"The lab technician working in a hospital used to send customers to him," the police said.

In the Srirampuram case, the medicine delivery boy had purchased vials MRP from a commissioning agent stating that he wanted the medicine to treat his brother.

In Karnataka, the price of Remdesivir ranges between Rs 899 and Rs 5,400 per vial. According to the available statistics, the retail price (MRP) for per vial for various brands of Remdesivir is Rs 5,400 for Hetero company, Rs 4,700 for Mylan, Rs 4,700 for Jubliant, Rs 5,400 for Reddy's, Rs 4,000 for Cipla and Rs 899 for Zydus.

--IANS

nbh/arm


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel